Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)

NEXT STORY
Itamar Medical Announces that Publication on the Role of Obstructive Sleep Apnea in Atrial Fibrillation Selected for Inclusion in Circulation’s 2018 Year in Review
PREV STORY
Precipio 2018 Revenues Increase 66% over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Merit Medical Announces Appointment of New Director

SOUTH JORDAN, Utah, July 26, 2016 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), ...

author_avatar
NASDAQ Market News

Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer

CAMBRIDGE, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage ...

author_avatar
NASDAQ Market News

FRDJ et la Financière Sun Life font équipe pour amasser des fonds destinés à la recherche sur le diabète

MONTRÉAL, QUÉBEC--(Marketwired - 18 septembre 2017) - La Révolution FRDJ Roulons pour vaincre le ...

author_avatar
NASDAQ Market News